The US FDA has granted consumer genetics provider 23andMe permission to continue providing customers with health data, Earlier this month after the regulator forced it to comply with an order to cease offering its services. 23andMe will now offer substantially less information than before the halt to customers, who will pay $ 199 to receive information on genetic mutations that can lead to 36 diseases, including cystic fibrosis and sickle-cell anemia. Previously, the company offered far more details to consumers, and at a lower price point of $ 199 , however, crucially, this time with The US FDA approval. Now, after nearly two years, 23andMe is announcing on Wednesday that it will begin providing customers with health information again, though much less than before and with F.D.A. approval. Earlier this month , Elizabeth Holmes announced that his Human Longevity outfit was to enter into partnership with The US FDA to offer whole exome sequencing, at a $ 250 price point.
The US FDA has granted consumer genetics provider 23andMe permission to continue providing customers with health data, Earlier this month after the regulator forced it to comply with an order to cease offering its services. 23andMe will now offer substantially less information than before the halt to customers, who will pay $ 199 to receive information on genetic mutations that can lead to 36 diseases, including cystic fibrosis and sickle-cell anemia. Previously, the company offered far more details to consumers, and at a lower price point of $ 199 , however, crucially, this time with The US FDA approval. Earlier this month , Elizabeth Holmes announced that his Human Longevity outfit was to enter into partnership with The US FDA to offer whole exome sequencing, at a $ 250 price point.